SFM
UPB

Soros Fund Management’s Upstream Bio Inc UPB Stock Holding History

Soros Fund Management’s Portfolio UPB Stock Details UPB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-46,350
Closed -$762K – 276
2024
Q4 		$762K Buy
+46,350
New +$1.03M 0.01% 184

Other funds holding UPB

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
DC
Decheng Capital Menlo Park, California $661M AUM 299.97% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
ES
Enavate Sciences Menlo Park, California $352M AUM 220.14% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
OFM
Omega Fund Management Boston, Massachusetts $163M AUM 107.06% 1-Year Est. Return

Soros Fund Management's UPB Position: Q1 2025 in Review

Soros Fund Management sold out of Upstream Bio Inc (UPB) in Q1 2025, closing a stake of 46,350 shares — an estimated $762K sold.

Soros Fund Management first reported a position in UPB in Q4 2024 and held it in 1 quarter. The position peaked at $762K in Q4 2024. 79 funds tracked by Wall St. Rank hold UPB as of Q1 2025.

  • Soros Fund Management reported no remaining Upstream Bio Inc position as of Q1 2025 after selling out during the quarter.
  • Soros Fund Management sold 46,350 Upstream Bio Inc shares in Q1 2025, an estimated $762K.
  • Soros Fund Management first reported a position in Upstream Bio Inc in Q4 2024 and held it in 1 quarter.
  • Soros Fund Management's Upstream Bio Inc position peaked at $762K in Q4 2024.
  • 79 funds tracked by Wall St. Rank held Upstream Bio Inc as of Q1 2025.

Based on Soros Fund Management's 13F filing for Q1 2025, filed 15 May 2025.